News

White House pulls Heidi Overton's FDA nomination a day before a Senate vote

Trump's pick to run the FDA lacked Republican votes on the Senate health committee. Why her bid stalled, who runs the agency now and what comes next.

By Published 4 min read
Sen. Bill Cassidy, in a navy suit and gold patterned tie, speaks at the Senate health committee dais behind his name placard.
File image: Sen. Bill Cassidy, chair of the Senate HELP Committee, speaks during Heidi Overton's confirmation hearing on Sept. 24, 2026. Still frame from the committee's public video.Photo: U.S. Senate Committee on Health, Education, Labor, and Pensions / Wikimedia Commons, Public domain

What happened

The White House withdrew Heidi Overton's nomination to lead the FDA on Tuesday night, Nov. 17, hours before the Senate health committee was set to vote on her. An administration official said she lacked the support in Congress to be confirmed.

Key takeaways

  • She needed 11 of the committee's 21 votes. With Democrats opposed, a single Republican defection would have sunk her.
  • Chairman Bill Cassidy called her part in rewriting childhood vaccine advice "almost disqualifying," Axios reported.
  • Kyle Diamantas keeps running the FDA as acting commissioner, a post he has held since Marty Makary resigned in May.
In this article

Published Tuesday, Nov. 17, 2026, 8:15 p.m. ET.

Heidi Overton won't be the next head of the Food and Drug Administration. The White House pulled her nomination Tuesday night, less than a day before the Senate health committee was due to vote on whether to send her to the full Senate.

Axios first reported the decision, and a White House official later confirmed it to NBC News. The reason given was blunt. Overton "lacks the support on the Hill to move forward with her confirmation," a senior administration official told Axios.

Read also: Breckenridge recalls propranolol capsules nationwide over possible metal contamination · FDA adds a blindness warning for Ozempic and all other GLP-1 drugs · Study ties energy drinks to cardiac arrest reports in young adults

That leaves the FDA, which oversees drugs, vaccines, tobacco and most of the country's food supply, without a confirmed leader for at least several more months.

Why Heidi Overton's FDA nomination fell apart

It came down to one committee and a very thin margin.

The Senate Health, Education, Labor and Pensions Committee has 21 members. Overton needed 11 votes to advance. With Democrats expected to vote no as a bloc, she could not lose a single Republican, NBC News noted. In the days before the vote, at least three of them still wouldn't say where they stood.

Bill Cassidy, the Louisiana Republican who chairs the committee, was the biggest problem. Before her September hearing he wrote on X that he had "strong concerns," pointing to her lack of experience running a large organization. He also objected to her part in the administration's push to change childhood vaccine recommendations, which he called "almost disqualifying," according to Axios. As recently as last week, he said he was undecided.

Susan Collins of Maine told NBC News last week that she had "not taken a position" and still needed answers.

Lisa Murkowski of Alaska declined to say how she would vote. At the hearing, she pressed Overton on political pressure over access to the abortion pill mifepristone and criticized her for not giving a clear answer.

The White House tried to steady things on Monday by posting a letter of support from a former dean of the University of New Mexico School of Medicine. By Tuesday evening, it had given up.

Pressure from both flanks

What made Overton's path unusual is that some of the doubts came from the president's own allies.

Parts of the Make America Healthy Again movement saw her as too friendly to health and agriculture interests and accused her of undercutting Health Secretary Robert F. Kennedy Jr.'s agenda, Axios reported. Anti-abortion groups, meanwhile, questioned whether she would really tighten the rules for prescribing mifepristone.

That last point mattered. Overton has praised the Supreme Court's decision to overturn Roe v. Wade and has called for strict limits on medication abortion, NBC reported. But she wouldn't commit to a position at the hearing, which left both sides of that debate uneasy.

Who is Heidi Overton?

Overton is a physician trained in preventive medicine. She serves as deputy director of the White House Domestic Policy Council, the office that shapes the president's health and social policy.

Most of her career has been spent working for Trump or for conservative groups tied to his agenda, the Associated Press reported. Before the White House, she was chief policy officer at the America First Policy Institute, a conservative think tank.

Trump nominated her in August. Her confirmation hearing on Sept. 24 produced few fireworks, Politico reported, but several key Republicans walked away unconvinced.

Who runs the FDA now?

Kyle Diamantas does, as acting commissioner. He has led the agency since Dr. Marty Makary resigned in May, according to Axios. NBC said Makary's exit was tied in part to the administration's decision to authorize several fruit-flavored vaping products.

Acting leaders can keep an agency running, but they usually have less political weight for big, contested calls. The FDA has one of those coming. Its safety review of mifepristone is set to wrap up in March, NBC reported, and it is one of the most closely watched decisions the agency faces.

The FDA is also the agency behind the drug safety alerts and recalls that land in people's medicine cabinets, like the recent case where Breckenridge recalls propranolol capsules nationwide over possible metal contamination. That routine work doesn't stop without a commissioner. Long-term policy, though, tends to stall.

What happens next for the FDA commissioner job

The administration says it wants "a new direction at FDA." The senior official told Axios the White House fully supports Kennedy's vision and a "more populist and common-sense approach" to health.

The calendar is now the hard part. Democrats take control of the Senate in January, and NBC noted that Overton would have had to be renominated then anyway, with slim odds. Any new pick will face a Democratic-led committee and will need to win over senators who have been critical of the Kennedy-era changes at the health agencies.

The White House hasn't named a replacement.

A familiar pattern at the health agencies

This isn't the first time a Trump health nominee has stalled in the Senate. The Centers for Disease Control and Prevention went almost a year without a permanent director after Kennedy removed Susan Monarez just 29 days into the job in 2025. Trump's first choice for that post, former Rep. Dave Weldon, couldn't line up enough Republican votes either. The agency cycled through acting leaders until the Senate confirmed Dr. Erica Schwartz in August, NBC reported.

That instability has played out against real public health problems. Earlier this month, the U.S. lost its measles elimination status as 2026 deaths reached 10, a setback that put vaccine policy and agency leadership back under the spotlight.

For now, the Senate health committee's Wednesday vote is off. The bigger question, who will lead the FDA through the mifepristone review and the rest of Kennedy's agenda, is wide open again.

Frequently asked questions

Who is Heidi Overton?
Heidi Overton is a physician trained in preventive medicine who serves as deputy director of the White House Domestic Policy Council. Before joining the Trump White House, she was chief policy officer at the America First Policy Institute, a conservative think tank. Trump nominated her to lead the FDA in August 2026.
Why was Heidi Overton's FDA nomination withdrawn?
The White House said she didn't have the votes. A senior administration official told Axios that Overton "lacks the support on the Hill" to be confirmed. Several Republicans on the Senate health committee, including chairman Bill Cassidy, Susan Collins and Lisa Murkowski, had not committed to backing her.
Who is the FDA commissioner now?
The FDA has no Senate-confirmed commissioner. Kyle Diamantas is acting commissioner and has led the agency since Dr. Marty Makary resigned in May 2026, according to Axios. He stays in charge until a new nominee is confirmed.
What happens next with the FDA commissioner nomination?
President Trump has to pick someone new. That person would face a harder road, because Democrats take control of the Senate in January, NBC News reported. Any nominee would need a committee hearing and a vote before reaching the full Senate.

Sources

  1. Scoop: White House drops Heidi Overton's FDA nomination · Axios, Nov. 17, 2026
  2. White House drops Heidi Overton's FDA nomination after Republicans raise concerns · NBC News, Nov. 17, 2026
  3. White House pulls FDA nominee Heidi Overton after wavering support from Senate Republicans · Associated Press, Nov. 17, 2026
  4. White House pulls FDA nominee amid bipartisan pushback · The Washington Post, Nov. 17, 2026
  5. Nomination of Heidi Overton to be Commissioner of Food and Drugs (hearing video) · U.S. Senate HELP Committee via Wikimedia Commons, Sept. 24, 2026

Tags

  • #Heidi Overton
  • #FDA
  • #FDA commissioner
  • #Bill Cassidy
  • #Senate HELP Committee
  • #Robert F. Kennedy Jr.
  • #Health policy

About the author

Marcia Reid

Founder and editor

Marcia Reid is the founder and editor of TrendCanopy, where she reviews and edits every story.

Editorial standards · Corrections

Spotted an error? Read our corrections policy or contact us. Last reviewed November 17, 2026.

Browse sections